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Background: Metabolic bone disease in patients with chron-
ic liver disease is called hepatic osteodystrophy and is prima-
rily a sequel to osteopenia/osteoporosis, and rarely second-
ary to osteomalacia. The aim of this work was to define the
influence of vitamin D3 and parathyroid hormone (PTH) in
the pathogenesis of hepatic osteodystrophy, as well as the
predictive significance of biochemical bone markers. 
Methods: This prospective study included 58 male patients
with alcoholic (49) and viral (9) cirrhosis. The concentrations
of serum vitamin D3, PTH, osteocalcin and b-carboxy-ter -
minal cross-linked telopeptide of type I collagen (b-CTX)
were determined. Bone density was measured by dual ener-
gy X-ray absorptiometry in the L1-L4 spinal segment and the
femoral neck. 
Results: Lower bone mineral density (BMD) was measured in
41 patients (70.7%). There was no significant correlation
between PTH and vitamin D3 values and T score in the
femoral neck (p=0.51; p=0.063) and lumbar spine
(p=0.49; 0.064). Also, no significant correlation was found
between the osteocalcin values in lumbar spine BMD
(p=0.944) and femoral neck (p=0.161), or with b-CTX
values and BMD in the lumbar spine (p=0.347) and femoral
neck (p=0.73). Statistically significant difference was con-
firmed between the stage A osteocalcin (p=0.000) and b-
CTX (p=0.008) values in relation to advanced stages B and
C. 
Kratak sadr`aj
Uvod: Metaboli~ka bolest kostiju kod pacijenata sa hro -
ni~nim oboljenjem jetre naziva se hepati~ka osteodistrofija i
primarno je posledica osteopenije ili osteoporoze a re|e
osteo malacije. Cilj rada je bio da se determini{e uloga para -
tireoidnog hormona (PTH) i vitamina D3 u patogenezi he -
pati~ke osteodistrofije, kao i prediktivni zna~aj biohemijskih
ko{tanih markera. 
Metode: U prospektivnoj studiji, obuhva}eno je 58 pacijena-
ta mu{kog pola sa alkoholnom (49) i virusnom (9) cirozom
jetre. Odre|ivane su serumske koncentracije vitamina D3,
PTH, osteokalcina i b-C-terminalnog telopeptida tip I kola -
gena (b-CTX). Ko{tana gustina je merena dvostrukom
X-zra~nom apsorpciometrijom na L1-L4 segmentu ki~me i
vratu butne kosti. 
Rezultati: Smanjena mineralna ko{tana gustina (BMD)
izmerena je kod 41 (70,7%) pacijenta. Nije bilo zna~ajne
korelacije vrednosti PTH i vitamina D3 sa T skorom na vratu
butne kosti (p=0,51; p=0,063) i lumbalnoj ki~mi (p=0,49;
p=0,064). Statisti~ka zna~ajnost nije uo~ena ni prilikom
upo re|ivanja vrednosti osteokalcina i BMD lumbalne ki~me
(p=0,944) i vrata butne kosti (p=0,161), kao ni vrednosti
b-CTX i BMD lumbalne ki~me (p=0,347) i vrata butne kosti
(p=0,73). Me|utim, statisti~ki zna~ajna razlika je potvr|e na
korelisanjem vrednosti osteokalcina (p=0,000) i b-CTX
(p=0,008) u stadijumu A u odnosu na odmakle stadijume
bolesti B i C. 
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Introduction
Impaired bone metabolism in liver cirrhosis brings
about pathological fractures, lower quality of life and
a higher mortality rate. Metabolic bone disease in
patients with chronic liver disease is called hepa tic
osteodystrophy and is primarily the consequence of
osteopenia or osteoporosis and considerably more
rare osteo malacia. Histopathological changes seen in
he patic osteodystrophy are similar to findings of post-
menopausal osteoporosis where the loss of trabecular
bone is more intensive than the loss of cortical bone
(1, 2). 
The genesis of hepatic osteodystrophy is multi-
factorial and, according to the different causes of liver
diseases, it may be caused by: a lower body mass
index (<19 kg/m2), reduced muscular mass, physical
inactivity, alcoholism, hyperbilirubinemia, lower in su -
lin-like growth factor 1 and osteoprotegerin levels, a
calcium deficit, a lowered vitamin D3 value, the vita-
min D receptor genotype, hypogonadism and other
hormonal disorders, increased tissue iron depositing,
long-term cholestasis, the use of antiviral medication
such as ribavirin, corticosteroids (prednisolone, 5
mg/day over 3 months) and immunosuppressive ther-
apy as well as liver insufficiency itself (3–5). 
It has been suggested that bone strength may
be assessed, independently of the bone mineral den-
sity (BMD) level, by measuring bone turnover using
specific serum and urinary markers of bone formation
and resorption (6).
The aim of the study was to define the influence of
vitamin D3 and parathyroid hormone (PTH) in the pat h -
ogenesis of hepatic osteodystrophy, as well as the pre -
dictive significance of the biochemical bone markers.
Patients and Methods 
Patients
A prospective study, conducted in the period
2010–2011, included 58 patients with liver cirrhosis
who were examined and treated at the Gastro -
enterology and Hepatology Clinic, Clinical Center of
Serbia, Belgrade. The concentrations of parathor-
mone, bone density markers and vitamin D3 were
measured at the Center for Biochemistry, Cli nical
Center of Serbia. Osteodensitometry was carried out
at the Railway Health Care Institute. 
Hepatologic examinations were focused on the
detection of the etiology of disease and differentiation
of the liver insufficiency extent. With this in mind, the
following diagnostic procedures were carried out: his-
tory and clinical examination, laboratory analysis,
ultrasonographic and histopathologic diagnostics.
Diagnosis of B viral cirrhosis was based on se ro -
logy (HBsAg, HBeAg, anti-HBe and anti-HBc IgG)
and determination of polymerase chain reaction hep-
atitis B virus deoxyribonucleic acid (PCR HBV DNA);
C viral cirrhosis was verified by the presence of anti-
HCV antibodies and detection and determination of
viral load per milliliter of blood (PCR HCV RNA).
Alcoholic cirrhosis was diagnosed on the basis of:
medical history data (consumption of pure alcohol
more than 50 g/day over a five-year period), clinical
and biochemical parameters and/or liver biopsy. The
study included only patients with at least a 6-month
abstinence period. 
The liver insufficiency degree, as determined by
the generally accepted Child-Pugh classification, was
divided into three stages: A, B and C (score: A ≤ 6; 7
< B < 9; C ≥ 10). The Child-Pugh score includes five
parameters: total bilirubin, serum albumins, INR,
ascites and hepatic encephalopathy (Table I) (7).
Females and patients with cholestatic diseases,
liver malignancy, portal venous system thrombosis,
earlier immobilization, renal failure, diabetes, hyper
and hypothyroidism, as well as patients treated by
corticosteroids, ribavirin, interferon and bisphospho-
nates were excluded from the study. 
Table I Child-Pugh classification.
Conclusions: PTH and vitamin D3 do not influence the
development of hepatic osteodystrophy. In patients with cir-
rhosis, osteocalcin and b-CTX are not valid indicators of
decreased BMD, but their values correlate with the degree of
liver insufficiency. 
Keywords: liver cirrhosis, osteoporosis, osteocalcin,
b-CTX
Zaklju~ak: PTH i vitamin D3 ne uti~u na razvoj hepati~ke
osteodistrofije. Kod pacijenata sa cirozom jetre osteokalcin i
b-CTX nisu validni pokazatelji smanjenja mineralne ko{tane
gustine, ali direktno koreli{u sa stepenom insuficijencije jetre.
Klju~ne re~i: ciroza jetre, osteoporoza, osteokalcin,
b-CTX
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Vitamin D status was evaluated by measuring
the 25-OH vitamin D3 after morning blood collec-
tion. 25-OH vitamin D3 was first extracted from 500
mL of serum by means of the original fluid-fluid
extraction procedure, which is an integral part of the
»Bio-Rad« HPLC reagent kit for vitamin D measu re -
ment. Fifty mL was injected in the HPLC line consist-
ing of: an isocratic HPLC pump »Waters 515«, an
auto-sampler »Waters 27-7«, a column heater, and a
UV/VIS detector »Waters 2489«. HPLC separation of
vitamins D3 and D2 was carried out by the original
mobile phase and column manufactured by the »Bio-
Rad« company. Column temperature was 40 °C, and
wavelength 265 nm. All concentrations were calculat-
ed by the manufacturer’s internal standard. Chroma -
to graphic data were processed by the original »Em -
power 2-Waters« chromatographic program. Normal
vitamin D values were > 32 ng/L. 
The intact PTH (N=15–65 pg/mL), N-MID
osteocalcin (N=14–46 mg/L), b-CTX (N=0–704
pg/mL) were determined by Elecsys®/Cobas eTM
reagents (Roche Diagnostics) on the Elecsys®
2010/cobas™ 601 immunoanalyzer (Roche Diag -
nostics) in compliance with the manufacturer’s
instructions. Detection was based on the electro-
chemiluminescent immunoassay (ECLIA), using the
tris (bipy ridyl)-ruthenium (II) complex (8).
Bone densitometry
All patients underwent dual energy X-ray absorp -
tiometry (DEXA) by means of a Hologyc Discovery
(S/N 83200) apparatus. The imaging of the femoral
neck and lumbar spine (L1–L4) was carried out.
According to the World Health Organisation recom-
mendations, normal bone mass was defined as T
score >-1 SD, osteopenia as T score ranging from -1
to -2.5 SD, osteoporosis as T score ≤-2.5 SD, and
severe osteoporosis as T score ≤2.5 along with bone
fractures. According to the same recommendations,
T score is a number of SD in relation to mean value
of BMD at the time of maximal bone mass (9).
Statistical analysis
Statistical analysis was performed using the
Statistical Package for Social Sciences (SPSS®, ver-
sion 17.0). Basic descriptive statistics included mean,
median, standard deviations, ranges and percent-
ages. Differences between groups were compared
with the parametric t-test or nonparametric Kruskal-
Wallis test. Correlation analysis was processed via the
Spearman method. Values at the p≤0.05 level were
considered statistically significant.
Results
The study included 58 male patients with liver
cirrhosis; mean age 54.1±9.8 years. The youngest
and the oldest patient were 26 and 75 years old,
respectively. Alcoholic cirrhosis was shown in 49
(84.4%) and viral C and B cirrhosis was diagnosed in
9 (15.6%) patients. Stages A, B and C were recorded
in 22 (37.9%), 17 (29.3%) and 19 (32.8%) patients,
respectively. 
Lower bone density was measured by osteoden-
sitometry in 41 patients (70.7%), of which osteopenia
was found in 31 (53.4%) and osteoporosis in 10
(17.3%) patients. T score <-1.0 was verified in 14
(63.6%) pa tients with the stage A, in 12 (70.6%) with
the stage B and 15 (78.9%) patients with the stage C.
No significant difference of T score and stage of dis-
ease was found (p=0.562). Mean BMD value of the
femoral neck in cirrhosis stage A was 0.806±0.13
g/cm2, and it was 0.780±0.14 g/cm2 in patients
with B + C stages. In stage A, mean BMD value of
the lumbar spine was 0.996±0.14 g/cm2, and in
stages B+C it was 1.015±0.16 g/cm2. There was
no significant difference between the femoral neck
BMD (p= 0.305) and lumbar spine (p=0.420), and
stage of the liver disease (Table II). 
Normal PTH values were found in 48 (82.7%)
patients and increased PTH values were found in 10
patients (17.3%). The average PTH values were in
stage A 81.46±67.12 pg/mL and in stages B+C
40.05±17.82 pg/mL. There was neither a statistically
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Table II Mineral bone density, PTH, vitamin D3 and bio-
chemical bone markers according to the Child-Pugh score. 
BMD (bone mineral density), PTH (parathyroid hormone),
b-CTX (b-carboxy-terminal cross-linked telopeptide of type I
collagen)
significant difference between the groups (p=0.77)
nor a significant correlation between PTH values and
T score in the femoral neck (p=0.51) and lumbar
spine (p=0.49) (Table II).
Lower vitamin D3 values were measured in 31
patients (53.5%). The average vitamin D3 values were
in stage A 38.23±23.93 ng/L and in stages B+C
29.12±16.73 ng/L. Although there was no statisti-
cally significant difference between the groups
(p=0.27), patients with advanced liver disease had
lower values of the vitamin D3. There was no signifi-
cant correlation between vitamin D3 values and T
score in the femoral neck (p=0.063) and lumbar
spine (p=0.064) (Table II). 
Osteocalcin values were lowered in 46 (79.3%)
patients. In stage A, reduced osteocalcin values were
measured in 14 (63.6%) patients, in stage B in 15
(88.2%), and in stage C in 17 (89.5%) patients
(Figure 1a). A significant difference between stage A
15.48±8.4 mg/L osteocalcin level and advanced
stages B+C 8.51±4.6 mg/L was found (p=0.000)
(Table II). Increased b-CTX values were obtained in
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23 (39.7%) patients. In the liver cirrhosis stage A,
higher b-CTX values were measured in 4 (18.2%)
patients, in stage B in 6 (35.3%) and in 13 (68.4%)
patients with the stage C (Figure 1b). A highly signi -
ficant difference between stage A 450.71±366.1
pg/mL b-CTX and stages B+C 739.2±381.2 pg/mL
was established (p=0.008) (Table II). There was no
sig nificant correlation between the osteocalcin values
in the lumbar spine (p=0.944) and femoral neck
(p=0.161), nor with b-CTX values and T score in the
lumbar spine (p=0.347) and femoral neck (p=0.73).
Discussion
The majority of authors agree that the preva-
lence of hepatic osteodystrophy in cholestatic dis-
eases is 15%–30% (primary sclerosing cholangitis
15%, primary biliary cirrhosis 20%–30%) (2). In con-
trast, regarding the parenchymal diseases, there is no
unique standpoint on the prevalence of hepatic osteo -
dystrophy (10). 
In the study of Cijevschi et al. (11) impaired
bone metabolism was confirmed in 32.5% of patients
with viral and in 47.3% of patients with alcoholic cir-
rhosis. A similar opinion was presented by Javad et al.
(12) who reported that, in patients with viral B or C
cirrhosis, osteopenia and osteoporosis were recorded
in 42% and 26% of patients, respectively. High fre-
quency of reduced bone density was reported by
George et al. (13) who described 72 patients with
alcoholic and viral cirrhosis out of whom 68% had
lower bone mineral density. 
In accord with the results of George et al, our
study also confirmed high frequency (70.7%) of
reduced BMD values.
The frequency and severity of osteoporosis in -
crease as the liver insufficiency progresses. However,
the study by Cijevschi et al. (11) reported that no sig-
nificant correlation between the BMD, severity and
etiology of the liver disease was found.
Similar to previous reports, our study failed to
confirm that the stage of liver cirrhosis interfered with
the T score. It was noted, however, that the frequen-
cy of osteopenia or osteoporosis, in the femoral neck,
increased with the higher degree of liver insufficiency.
The role of the calcium-PTH-vitamin D axis in
hepatic osteodystrophy is controversial. Some authors
reported that PTH was increased in liver insufficiency,
while others underscored that PTH values were nor-
mal or even reduced in this condition. The prevailing
opinion is that the changes in PTH concentrations
have no significant effect on the development of osteo -
 porosis in cirrhotic patients (10, 14, 15). Although
vitamin D inadequacy is very common with these
patients, secondary hyperparathyroidism is rather rare
(16).
Our results also suggested that PTH values had
no significant impact on hepatic osteodystrophy.
The latest studies have demonstrated very high
prevalence of vitamin D deficiency and insufficiency in
patients with chronic liver disease and cirrhosis (17).
Recently, it has been recognised that vitamin D also
regulates cell proliferation and differe ntiation, and has
immunomodulatory, antiinflammatory and antifibrotic
properties. The role of vitamin D in the activation and
regulation of both innate and adaptive immune sys-
tems may explain its importance in the liver diseases
(18).
However, in spite of the decreased value of vita-
min D particularly in advanced cirrhosis patients, the
influence of the lower 25-hydroxy vitamin D3 values
on the BMD was not determined in the study of Gon -
zales-Calvin et al. (15). Based on regression analysis,
the authors concluded that, in cirrhotic patients, 25-
hydroxy vitamin D3 was not a valid predictor of osteo-
porosis. 
Furthermore, in the pathogenesis of hepatic
osteo dystrophy, reduced tissue sensitivity to circula -
ting vitamin due to a modified vitamin D receptor ge -
notype may have a role. In healthy people and
patients with postmenopausal osteoporosis, polymor-
phism of the vi tamin D receptor alleles designated
as: B/b, a/a and T/t alleles correlates with the bone
mineral density (3).
Similar to previous studies, in our analyses,
patients with advanced disease had a lower vitamin
D3 level, but there was no statistical confirmation of
the effect of vitamin D3 levels on BMD values. 
The rates of bone production and destruction
can be evaluated either by measuring predominantly
osteoblastic or osteoclastic enzyme activities or by
assaying bone matrix components released into the
bloodstream and excreted in the urine. The most sen-
sitive markers for bone formation are serum total
osteocalcin, bone alkaline phosphatase and the pro-
collagen type I N-terminal propeptide. For the evalu-
ation of bone resorption, most assays are based on
the detection in serum or urine of type I collagen frag-
ments. These include free pyridinoline and deoxy -
pyridinoline, pyridinoline cross-linking telopeptides
(b-CTX and N-terminal cross-linked telopeptide type
I collagen) (19–21).
In cases of increased values of the bone ALP,
osteocalcin and CTX, screening should be done for
osteoporosis, in particular associated to high bone
remodeling diseases such as hyperparathyroidism or
endogenous hypercorticisolism, or unknown vertebral
fracture (22).
George et al. (13) while analyzing a group of
72 patients with viral liver cirrhosis confirmed lower
osteocalcin values in 68% of subjects and increased
J Med Biochem 2014; 33 (2) 153
free deoxypyridinoline in 79% of patients. Sub se -
quently, Goral et al. (10) reported that lower values of
osteocalcin as a marker of bone formation were
found in patients with virus B and C liver cirrhosis.
Decreased osteocalcin values and increased val-
ues of b-CTX were also confirmed in our study. There
was no significant correlation between the bone
metabolism markers values and bone mineral density
in the lumbar spine and femoral neck. However, a
reduction in serum osteocalcin and increase in b-CTX
can be explained by impaired osteoblast activity with
reduced synthesis of collagen matrix and increased
osteoclastic activity with bone resorption.
Conclusion
PTH and vitamin D3 do not influence the devel-
opment of hepatic osteodystrophy. In the patients
with cirrhosis, osteocalcin and b-CTX are not valid
indicators of decreased bone mineral density, but
their values correlate well with the degree of liver
insufficiency. 
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